Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: Excellent tolerance using subcutaneous amifostine for cytoprotection

British Journal of Cancer

Volumn 87, Issue 4, 2002, Pages 385-392

  Koukourakis, M I ^a   Romanidis, K ^a   Froudarakis, M ^b   Kyrgias, G ^c   Koukourakis, G V ^c   Retalis, G ^a   Bahlitzanakis, N ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Venizelion General Hospital   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Amifostine; Docetaxel; Non small cell lung cancer; Radiotherapy; Stealth liposomal doxorubicin

Indexed keywords

AMIFOSTINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; METHYLPREDNISOLONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RANITIDINE; TROPISETRON;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESOPHAGITIS; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RASH; SIDE EFFECT; TREATMENT OUTCOME;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037068350     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600486     Document Type: Article

References (39)

1. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer
2. Apoptosis after genotoxic damage is enhanced by Taxol induced phosphorylation of bcl-2 and correlates with nuclear import of p53
3. Doxorubicin decreases the repair of radiation-induced DNA damage
4. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study
5. Phase III study of concurrent versus sequential thoracic radiotherapy incombination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
6. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer
7. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
8. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model
9. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes
10. The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes
11. Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model
12. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells
13. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
14. Retrospective and prospective tumor staging evaluating prognostic factors in operable bronchus carcinoma patients
15. Randomized phase III study of chemoradiation±amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC)
16. The impact of overall treatment time on the results of radiotherapy for non-small cell lung cancer
17. Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/II dose escalation trial
18. Fractionated carboplatin radiosensitization. A phase I dose escalation study
19. Concurrent twice-a-week docetaxel and radiotherapy. A dose escalation trial with immunological toxicity evaluation
20. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatement of locally advanced non-small cell lung cancer and head and neck cancer
21. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small cell lung carcinoma
22. Subcutaneous Administration of Amifostine during Fractionated Radiotherapy: A randomized phase II study
23. High intratumoral accumulation of stealth® liposomal doxorubicin (Caelyx®) in locally advanced sarcomas provides strong rational for combination with radiotherapy
24. A phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF, in patients with incomplete response following docetaxel chemo-radiotherapy. Additional chemotherapy enhances regression of residual cancer
25. Docetaxel-induced lymphopenia in patients with solid tumors. A prospective phenotypic analysis
26. Protective effect of amifostine (AMF) on doxil/caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients with advanced cancer
27. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis
28. Enhancement of tumor radioresponse in vivo by gemcitabine
29. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small cell lung cancer
30. LENT SOMA tables
31. Randomized multicenter trials of CHART vs conventional radiotherapy in head-neck and non-small cell lung cancer. An interim report
32. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
33. Systemic inflammatory response syndrome associated with amifostine
34. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors
35. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts
36. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer
37. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
38. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in human tumor xenografts